THE FUTURE OF TENDON AND LIGAMENT INJURY REPAIR IS HERE
PAX Therapeutics is a preclinical-stage gene delivery company relentlessly focused on bringing gene delivery out of the lab and into the clinical settings for patients with tendon and ligament injury.
Our initial product candidate, PAX-001, is our proprietary gene therapy currently in development for the treatment of flexor tendon injuries of the hand.
A BETTER THERAPY: PAX-001
PAX-001 is our proprietary vector- a cutting edge, yet proven gene delivery technology for hyperlocalized production of VEGF, a growth factor that stimulates the production of Type 1 collagen. The vector is AAV-2 which has been approved for use in children for another disease, and is in widespread clinical trials for other diseases.
HUMANS: This results in a stronger healed tendon following repair surgery for humans (so less re-rupture) and a faster ability to start using the joint, along with fewer adhesions, (scarring) yielding better joint mobility and decreased pain.
HORSES: Current therapies are so unproven that many a significant proportion of horses are euthanized after injury. For those treated by existing therapies, PAX-001 offers the production of Type 1 collagen instead of Type 3 collagen will mean that the typical process or remodeling from Type 3 to Type 1 collagen will not be needed.
FACILE DELIVERY: LOCAL INJECTION
PAX-001 is easily delivered by injection during repair surgery in humans and by Ultrasound-guided injection through the skin in horses.
PROGRESSION TO THE CLINIC
PAX-001 is about to enter GLP studies prior to filing an IND for human clinical trials of flexor tendon injury repairs in humans. A pilot study in horses, intended to expand to an IND-enabling field trial is planned to start by the end of 2020.
